Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Accumulated Expenses: 2013-2019

Historic Accumulated Expenses for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $1.7 million.

  • Soleno Therapeutics' Accumulated Expenses rose 49.09% to $1.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $1.7 million, marking a year-over-year increase of 49.09%. This contributed to the annual value of $274,000 for FY2018, which is 71.84% down from last year.
  • Per Soleno Therapeutics' latest filing, its Accumulated Expenses stood at $1.7 million for Q3 2019, which was up 54.17% from $1.1 million recorded in Q2 2019.
  • Over the past 5 years, Soleno Therapeutics' Accumulated Expenses peaked at $1.7 million during Q3 2019, and registered a low of $274,000 during Q4 2018.
  • In the last 3 years, Soleno Therapeutics' Accumulated Expenses had a median value of $976,000 in 2017 and averaged $991,000.
  • In the last 5 years, Soleno Therapeutics' Accumulated Expenses soared by 710.44% in 2015 and then crashed by 71.84% in 2018.
  • Soleno Therapeutics' Accumulated Expenses (Quarterly) stood at $1.6 million in 2015, then crashed by 35.66% to $1.1 million in 2016, then fell by 7.37% to $973,000 in 2017, then tumbled by 71.84% to $274,000 in 2018, then surged by 49.09% to $1.7 million in 2019.
  • Its Accumulated Expenses stands at $1.7 million for Q3 2019, versus $1.1 million for Q2 2019 and $992,000 for Q1 2019.